Scientists from the Biosanitary Research Institute of Granada (ibs.GRANADA) have shown that the presence in blood of RNA from genes closely related to the process of angiogenesis –Essential phenomenon in the growth and metastatic expansion of a tumor– is excellent biomarkers to detect the Cancer.
The team has succeeded in showing these genes in the blood through a Digital PCR (dPCR), a highly sensitive technology that would allow to obtain rapid results in the detection and prognosis of the colon cancer. The results are published in the Journal Clinical Medical and Scientific Report.
Despite the important advances in the treatment and diagnosis of colon cancer, a very important number of patients present metastasis when detected or develop it throughout the evolution of the disease
One of the main findings is that some of the genes analyzed – such as those called GUCY2C and GUCY2C / PTGS2– can predict the response of patients to treatment, which could open the door to their use as a new indicator to design a more personalized medicine.
Colon cancer is the third most common tumor in the world and the second cause of cancer death. In Spain, and considering both sexes, it is the most common cancer, currently surpassing breast and lung cancer.
Despite the important advances in its treatment and the improvement in its early diagnosis, a very important number of patients present metastasis at the time of diagnosis or they develop it throughout the evolution of the disease. Therefore, it is a priority for experts to detect the disease early and develop strategies to optimize its prognosis and the efficacy of the applied therapy.
Study and description of metabolites in patients and controls. / ibs.GRANADA
Knowledge about possible markers
This research is the continuation of the search for new biomarkers for metastatic colon cancer using methodologies as novel as metabolomics, which allows detecting the presence of low molecular weight molecules in patients.
The application of this technology has made it possible to obtain a ‘fingerprint’ for the detection of this pathology through five compounds of three classes of molecules (sphingolipids, endocannabinoids and glycerophospholipids) present in the blood of patients.
UGR – University of Granada
Rights: Creative Commons.